<p><strong>Renal Impairment</strong>: No dosage adjustment is necessary for patients with renal impairment.<br />
<br />
<strong>Hepatic Impairment</strong>: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary.<br />
<br />
<strong>Pediatric Use</strong>: The safety and effectiveness of Bicalutamide in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: In two studies in patients given 50 or 150 mg daily, no significant relationship between age and steady-state levels of total bicalutamide or the active R-enantiomer has been shown.<br />
<br />
<strong>Women</strong>: Bicalutamide has not been studied in women.</p>